Passage Bio Inc expected to post a loss of 89  cents a share - Earnings Preview

Passage Bio

01/03/2022 13:54

* Passage Bio Inc  PASG.OQ   PASG.O  is expected to show no
change
in quarterly revenue when it reports  results on March 3. 
    * ​Refinitiv's mean analyst estimate for Passage Bio Inc is
for a
loss of 89 cents per share. For the same quarter last year, the
company reported a loss of 85 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Passage Bio
Inc
is $24​, about 86.2% above​ its last closing price of $3.32. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.89       -0.86      -0.87     Missed  -1
 Jun. 30 2021  -0.76       -0.76      -0.90     Missed  -18.9
 Mar. 31 2021  -0.75       -0.74      -0.76     Missed  -2.2​
 Dec. 31 2020  -0.69       -0.70      -0.85     Missed  -21
 ​​Sep.        -0.78       -0.76      -0.63     Beat    17.1
 30 2020                                                
 Jun. 30 2020  -0.57       -0.57      -0.60     Missed  -5.3​
 Mar. 31 2020  -0.45       -0.45      -1.00     Missed  -123.9
 This summary was machine generated March 1 at 13:54 GMT.  All
figures in US dollars  unless otherwise stated